Lachman Consultants Management Team
Lachman Consultants is led by a proven management team that includes:
- Leon Lachman, Ph.D. Chairman of the Board
- Paul Vogel, Chief Executive Officer
- Roy Sturgeon, Ph.D. President
- Frank Chow, Ph.D. Executive Vice President
- David Petshaft, Esq., Executive Vice President
- Robert Pollock, M.S., R.Ph. Senior Advisor
- Arlene Ocampo, Ph.D. Senior Vice President
- Joan Janulis, R.A.C. Vice President
- James Davidson, Ph.D. Vice President
- Edmund Fry, Executive Director
- Robert Moore, Senior Director
- Eric Richmond, Ph.D. Senior Director
- Carol Brandt, M.S. Senior Director
- Mary-Anne D'Esposito, M.S. Director
- David Jaworski, Director
Robert W. Pollock, M.S., R.Ph.
Senior Advisor, Outside Director to the Board
R.Pollock@LachmanConsultants.com
Robert Pollock is the Senior Advisor, Outside Director to the Board at Lachman Consultants. He joined Lachman Consultants following a distinguished career with the FDA and the Public Health Service. His FDAexperience, culminating as the Acting Deputy Director of the Office of Generic Drugs, enables him to provide expert advice and assistance on all aspects ofFDA and Regulatory filings. Mr. Pollock is well-versed in the intricacies of International Harmonization Issues,regulatory strategies, standards and filing issues, resolution of FDA regulatory matters, as well as in the resolution of patent / exclusivityissues.
Expertise
- Specialist in Regulatory Affairs
- Perform facility and documentation audits
- Assist and develop strategic alliances
- Develop and present training programs
- Review and prepare NDAs, ANDAs, petitions, and other regulatory filings
- Liaise with top executives of the pharmaceutical industry, professional organizations, Congress, health care providers, other federal and state agencies, and special-interest and consumer groups on all matters relating to the drug review and approval process
- Provide representation before national and international professional and governmental organizations
- Coordinate/provide regulatory, scientific, and technical support during the drug review process
- Direct the review of labeling of U.S. approved generic drugs
- Represent pharmaceutical manufacturers before state and federal agencies on issues pertaining to the NDA or ANDA drug review and approval process as it relates to national health issues and goals
- Coordinate with industry officials, professional organizations, health organizations, health care professionals and consumer groups on all matters relating to the drug review and approval
- Direct the review of labeling of U.S. approved generic drugs
- Represent pharmaceutical manufacturers before State and Federal Agencies on issues pertaining to the NDA or ANDA
Learn More about Lachman
For more information about how Lachman Consultants can help you prevent and resolve compliance and other scientific or regulatory issues, please contact us today.